UniProt P0C6U8
3C-like proteinase (P0C6U8)
3C-like proteinase (UniProt P0C6U8), EC 3.4.19.12, 3.4.22.-: 146 experimental structures on GenesisL1, 23 ligands bound, 8 pockets. Binding sites, pockets, druggability and 3D structures in GL1X.
- UniProt
- P0C6U8
- Protein
- 3C-like proteinase
- EC
- 3.4.19.12, 3.4.22.-, 3.4.22.69
- Experimental structures
- 146
- Predicted models
- 0
- Ligands
- 23
- Pockets
- 8 · 2 records with a druggable one
Structures
146 records of P0C6U8 in the MolNFT archive: 146 experimental, 0 predicted.
| Entry | Title | Method | Chains | Ligands | Pockets |
|---|---|---|---|---|---|
| 1Q2W | X-Ray Crystal Structure of the SARS Coronavirus Main Protease | x-ray diffraction | A, B | — | — |
| 1Q2W | X-ray crystal structure of the SARS coronavirus main protease | x-ray diffraction | A, B | — | — |
| 2BX3 | Crystal Structure of SARS Coronavirus Main Proteinase (P43212) | x-ray diffraction | A | — | — |
| 2BX4 | Crystal Structure of SARS Coronavirus Main Proteinase (P21212) | x-ray diffraction | A | — | — |
| 2BX4 | Crystal structure of SARS coronavirus main proteinase (P21212) | x-ray diffraction | A | — | — |
| 2K87 | NMR structure of a putative RNA binding protein (SARS1) from SARS coronavirus | solution nmr | A | — | — |
| 2K87 | NMR structure of a putative RNA binding protein (SARS1) from SARS coronavirus | solution nmr | A | — | — |
| 2KAF | Solution structure of the SARS-unique domain-C from the nonstructural protein 3 (nsp3) of the… | solution nmr | A | — | — |
| 2KAF | Solution structure of the SARS-unique domain-C from the nonstructural protein 3 (NSP3) of the… | solution nmr | A | — | — |
| 2KQV | SARS coronavirus-unique domain (SUD): Three-domain molecular architecture in solution and RNA… | solution nmr | A | — | — |
| 2KQV | SARS coronavirus-unique domain (sud): three-domain molecular architecture in solution and RNA… | solution nmr | A | — | — |
| 2KQW | SARS coronavirus-unique domain (SUD): Three-domain molecular architecture in solution and RNA… | solution nmr | A | — | — |
| 2KQW | SARS coronavirus-unique domain (sud): three-domain molecular architecture in solution and RNA… | solution nmr | A | — | — |
| 2KYS | NMR Structure of the SARS Coronavirus Nonstructural Protein Nsp7 in Solution at pH 6.5 | solution nmr | A | — | — |
| 2KYS | NMR structure of the SARS coronavirus nonstructural protein NSP7 in solution at pH 6.5 | solution nmr | A | — | — |
| 2LIZ | NMR solution structure of C-terminal domain of SARS-CoV main protease in 2.5M urea | solution nmr | A | — | — |
| 2LIZ | NMR solution structure of C-terminal domain of SARS-cov main protease in 2.5M urea | solution nmr | A | — | — |
| 2W2G | Human SARS coronavirus unique domain | x-ray diffraction | A, B | — | — |
| 2W2G | Human SARS coronavirus unique domain | x-ray diffraction | A, B | — | — |
| 2WCT | human SARS coronavirus unique domain (triclinic form) | x-ray diffraction | A, B, C, D | — | — |
| 2WCT | Human SARS coronavirus unique domain (triclinic form) | x-ray diffraction | A, B, C, D | — | — |
| 2ZU4 | Complex structure of SARS-CoV 3CL protease with TG-0204998 | x-ray diffraction | A | — | — |
| 2ZU4 | Complex structure of SARS-cov 3CL protease with tg-0204998 | x-ray diffraction | A | — | — |
| 2ZU5 | complex structure of SARS-CoV 3CL protease with TG-0205486 | x-ray diffraction | A | — | — |
| 2ZU5 | Complex structure of SARS-cov 3CL protease with tg-0205486 | x-ray diffraction | A | — | — |
| 3ATW | Structure-Based Design, Synthesis, Evaluation of Peptide-mimetic SARS 3CL Protease Inhibitors | x-ray diffraction | A, B | — | — |
| 3ATW | Structure-based design, synthesis, evaluation of peptide-mimetic SARS 3CL protease inhibitors | x-ray diffraction | A, B | — | — |
| 3AVZ | Structure of SARS 3CL protease with peptidic aldehyde inhibitor containing cyclohexyl side chain | x-ray diffraction | A | — | — |
| 3AVZ | Structure of SARS 3CL protease with peptidic aldehyde inhibitor containing cyclohexyl side chain | x-ray diffraction | A | — | — |
| 3AW0 | Structure of SARS 3CL protease with peptidic aldehyde inhibitor | x-ray diffraction | A | — | — |
| 3AW0 | Structure of SARS 3CL protease with peptidic aldehyde inhibitor | x-ray diffraction | A | — | — |
| 3AW1 | Structure of SARS 3CL protease auto-proteolysis resistant mutant in the absent of inhibitor | x-ray diffraction | A, B | — | — |
| 3AW1 | Structure of SARS 3CL protease auto-proteolysis resistant mutant in the absent of inhibitor | x-ray diffraction | A, B | — | — |
| 3E91 | Crystal structure of SARS-CoV Mpro mutant in P21 at pH6.9 | x-ray diffraction | A, B | — | — |
| 3E91 | Crystal structure of SARS-cov mpro mutant in P21 at PH6.9 | x-ray diffraction | A, B | — | — |
| 3E9S | A new class of papain-like protease/deubiquitinase inhibitors blocks SARS virus replication | x-ray diffraction | A | — | — |
| 3E9S | A new class of papain-like PROTEASE/DEUBIQUITINASE inhibitors blocks SARS virus replication | x-ray diffraction | A | — | — |
| 3EA7 | Crystal structure of SARS-CoV main protease triple mutant STI/A in space group P21 | x-ray diffraction | A, B | — | — |
| 3EA7 | Crystal structure of SARS-cov main protease triple mutant STI/A in space group P21 | x-ray diffraction | A, B | — | — |
| 3EA8 | Crystal structure of SARS-CoV main protease triple mutant STI/A in space group C2 | x-ray diffraction | A | — | — |
| 3EA8 | Crystal structure of SARS-cov main protease triple mutant STI/A in space group C2 | x-ray diffraction | A | — | — |
| 3EA9 | Crystal structure of SARS-CoV main protease quadruple mutant STIF/A with one molecule in one… | x-ray diffraction | A | — | — |
| 3EA9 | Crystal structure of SARS-cov main protease quadruple mutant STIF/A with one molecule in one… | x-ray diffraction | A | — | — |
| 3EAJ | Crystal structure of SARS-CoV main protease quadruple mutant STIF/A with two molecules in one… | x-ray diffraction | A, B | — | — |
| 3EAJ | Crystal structure of SARS-cov main protease quadruple mutant STIF/A with two molecules in one… | x-ray diffraction | A, B | — | — |
| 3EE7 | Crystal Structure of SARS-CoV nsp9 G104E | x-ray diffraction | A, B, C, D | — | — |
| 3EE7 | Crystal structure of SARS-cov NSP9 G104E | x-ray diffraction | A, B, C, D | — | — |
| 3F9E | Crystal Structure of the S139A mutant of SARS-Coronovirus 3C-like Protease | x-ray diffraction | A | — | — |
| 3F9E | Crystal structure of the S139A mutant of SARS-coronovirus 3C-like protease | x-ray diffraction | A | — | — |
| 3F9F | Crystal Structure of the F140A mutant of SARS-Coronovirus 3C-like Protease at pH 6.0 | x-ray diffraction | A, B | — | — |
| 3F9F | Crystal structure of the F140A mutant of SARS-coronovirus 3C-like protease at pH 6.0 | x-ray diffraction | A, B | — | — |
| 3F9G | Crystal Structure of the F140A mutant of SARS-Coronovirus 3C-like Protease at pH 6.5 | x-ray diffraction | A, B | — | — |
| 3F9G | Crystal structure of the F140A mutant of SARS-coronovirus 3C-like protease at pH 6.5 | x-ray diffraction | A, B | — | — |
| 3F9H | Crystal Structure of the F140A mutant of SARS-Coronovirus 3C-like Protease at pH 7.6 | x-ray diffraction | A, B | — | — |
| 3F9H | Crystal structure of the F140A mutant of SARS-coronovirus 3C-like protease at pH 7.6 | x-ray diffraction | A, B | — | — |
| 3FZD | Mutation of Asn28 disrupts the enzymatic activity and dimerization of SARS 3CLpro | x-ray diffraction | A | — | — |
| 3FZD | Mutation of ASN28 disrupts the enzymatic activity and dimerization of SARS 3CLPRO | x-ray diffraction | A | — | — |
| 3IWM | The octameric SARS-CoV main protease | x-ray diffraction | A, B, C, D | — | — |
| 3IWM | The octameric SARS-cov main protease | x-ray diffraction | A, B, C, D | — | — |
| 3M3S | Crystal structure of SARS-COV main protease Asn214Ala mutant with authorize N-terminus | x-ray diffraction | A, B | — | — |
86 records more on the page itself.
Ligands
- ZN · Zinc ion · in 5 records
- 4WI · (1R,2S,5S)-N-{(1E,2S)-1-imino-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl}-6,6-dimethyl-3-[3-methyl-N-(trifluoroacetyl)-L-valyl]-3-azabicyclo[3.1.0]hexane-2-carboxamide · in 2 records
- CL · Chloride ion · in 2 records
- EOF · (2~{S})-4-methyl-~{N}-[(2~{S})-1-oxidanylidene-3-[(3~{S})-2-oxidanylidenepyrrolidin-3-yl]propan-2-yl]-2-[[(~{E})-3-phenylprop-2-enoyl]amino]pentanamide · in 2 records
- GVE · Methyl 4-aminobutanoate · in 2 records
- NA · Sodium ion · in 2 records
- V3D · (3S)-3-{[N-(4-methoxy-1H-indole-2-carbonyl)-L-leucyl]amino}-2-oxo-4-[(3S)-2-oxopyrrolidin-3-yl]butyl 2-cyanobenzoate · in 2 records
- 3WL · 5,6,7-trihydroxy-2-phenyl-4H-chromen-4-one · in 1 record
- 4IO · 5-chloropyridin-3-yl 1-(3-nitrobenzene-1-sulfonyl)-1H-indole-5-carboxylate · in 1 record
- 73O · (2~{S})-2-azanyl-4-(4-hydroxyphenyl)butanoic acid · in 1 record
- ACE · Acetyl group · in 1 record
- B1S · (1R,2S)-2-({N-[(benzyloxy)carbonyl]-L-leucyl}amino)-1-hydroxy-3-[(3S)-2-oxopyrrolidin-3-yl]propane-1-sulfonic acid · in 1 record
- EOC · (2~{S})-4-methyl-~{N}-[(2~{S})-1-oxidanylidene-3-[(3~{S})-2-oxidanylidenepiperidin-3-yl]propan-2-yl]-2-[[(~{E})-3-phenylprop-2-enoyl]amino]pentanamide · in 1 record
- FNO · 2-[(1R)-4-methyl-1-oxidanyl-pent-3-enyl]-5,8-bis(oxidanyl)naphthalene-1,4-dione · in 1 record
- J7R · ~{N}-[(1~{S},2~{R})-2-[[4-bromanyl-2-(methylcarbamoyl)-6-nitro-phenyl]amino]cyclohexyl]isoquinoline-4-carboxamide · in 1 record
- K36 · (1S,2S)-2-({N-[(benzyloxy)carbonyl]-L-leucyl}amino)-1-hydroxy-3-[(3S)-2-oxopyrrolidin-3-yl]propane-1-sulfonic acid · in 1 record
- NH4 · Ammonium ion · in 1 record
- QYS · (1S,2S)-2-[(N-{[(4,4-difluorocyclohexyl) methoxy]carbonyl}-L-leucyl)amino]-1-hydroxy-3-[(3S)-2-oxopyrrolidin-3-yl]propane-1-sulfonic acid · in 1 record
- SO4 · Sulfate ion · in 1 record
- V2M · N-[(2S)-1-({(2S,3S)-3,4-dihydroxy-1-[(3S)-2-oxopyrrolidin-3-yl]butan-2-yl}amino)-4-methyl-1-oxopentan-2-yl]-4-methoxy-1H-indole-2-carboxamide · in 1 record
- V34 · Ethyl (2E,4S)-4-{[N-(4-methoxy-1H-indole-2-carbonyl)-L-leucyl]amino}-5-[(3S)-2-oxopyrrolidin-3-yl]pent-2-enoate · in 1 record
- VDJ · [4,4-bis(fluoranyl)cyclohexyl]methyl ~{N}-[(2~{S})-1-[[(1~{R},2~{S})-1-[bis(oxidanyl)-oxidanylidene-$L^{5}-sulfanyl]-1-oxidanyl-3-[(3~{S})-2-oxidanylidenepyrrolidin-3-yl]propan-2-yl]amino]-4-methyl-1-oxidanylidene-pentan-2-yl]carbamate · in 1 record
- VR4 · N-{(2S,3R)-4-(benzylamino)-3-hydroxy-4-oxo-1-[(3S)-2-oxopyrrolidin-3-yl]butan-2-yl}-N~2~-[(benzyloxy) carbonyl]-L-leucinamide · in 1 record
Elsewhere
GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.